Timing of Pegfilgrastim: Association with Febrile Neutropenia in a Pediatric Solid and CNS Tumor Population

Aapro, M., Boccia, R., Leonard, R., Camps, C., Campone, M., Choquet, S., DAnova, M., Glaspy, J., Hus, I., Link, H., Sliwa, T., Tesch, H., Valero, V. (2017). Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: Consensus guidance recommendations. Supportive Care in Cancer, 25(11), 3295-3304. https://doi.org/10.1007/s00520-017-3842-1
Google Scholar | Crossref | Medline Amgen . (2020). Pegfilgrastim: full prescribing information. https://www.pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/neulasta/neulasta_pi_hcp_english.pdf
Google Scholar Andre, N., Kababri, M. E., Bertrand, P., Rome, A., Coze, C., Gentet, J. C., Bernard, J. L. (2007). Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anti-Cancer Drugs, 18(3), 277-281. https://doi.org/10.1097/CAD.0b013e328011a532
Google Scholar | Crossref | Medline | ISI Billingsley, C. C., Jacobson, S., Crafton, S., Crim, A., Li, Q., Hade, E., Cohn, D., Fowler, J., Copeland, L., Salani, R., Backes, F., O’Malley, D. (2015). Evaluation of the hematologic safety of same day versus standard administration (24- to 72-hour delay) of pegfilgrastim in gynecology oncology patients undergoing cytotoxic chemotherapy. International Journal of Gynecologic Cancer, 25(7), 1331-1336. https://doi.org/10.1097/IGC.0000000000000487
Google Scholar | Crossref | Medline Borinstein, S. C., Pollard, J., Winter, L., Hawkins, D. S. (2009). Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors. Pediatric Blood and Cancer, 53, 375-378. https://doi.org/10.1002/pbc.22086
Google Scholar | Crossref | Medline Fox, E., Widemann, B. C., Hawkins, D. S., Jayaprakash, N., Dagher, R., Aikin, A. A., Bernstein, D., Long, L., Mackall, C., Helman, L., Steinbert, S. M., Balis, F. M. (2009). Randomized trial and pharmacokinetic study of pegfilgrastim vs. filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. Clinical Cancer Research, 15(23), 7361-7367. https://doi.org/10.1158/1078-0432.CCR-09-0761
Google Scholar | Crossref | Medline Haeusler, G. M., Phillips, R. S., Lehrnbecher, T., Thursky, K. A., Sung, L., Ammann, R. A. (2014). Core outcomes and definitions for pediatric fever and neutropenia research: A consensus statement from an international panel. Pediatric Blood & Cancer, 62(3), 483-489. https://doi.org/10.1002/pbc.25335
Google Scholar | Crossref | Medline Li, Y., Klippel, Z., Shih, X., Wang, H., Reiner, M., Page, J. (2016). Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy. Cancer Chemotherapy Pharmacology, 77, 703-712. https://doi.org/10.1007/s00280-016-2970-5
Google Scholar | Crossref | Medline Lyman, G. H. (2009). Impact of chemotherapy dose intensity on cancer patient outcomes. Journal of the National Comprehensive Cancer Network, 7(1), 99-108. https://doi.org/doi:10.6004/jnccn.2009.0009
Google Scholar | Crossref | Medline Lyman, G. H., Alcott, K., Garcia, J., Stryker, S., Li, Y., Reiner, M. T., & Weycker, D. (2017). The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: A systematic review. Supportive Care in Cancer, 25(8), 2619. https://doi.org/10.1007/s00520-017-3703-y
Google Scholar | Crossref | Medline Marion, S., Tzivelekis, S., Darden, C., Price, M., Sherif, B., Garcia, J., Kaye, J., Chandler, D. (2016). “Same-Day” administration of pegfilgrastim following myelosuppressive chemotherapy: Clinical practice and provider rationale. Supportive Care in Cancer, 24, 3889-3896. https://doi.org/10.1007/s00520-016-3193-3
Google Scholar | Crossref | Medline Schuman, S., Lambrou, N., Robson, K., Gluck, S., Myriounis, N., Pearson, M., Lucci, J. (2009). Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. Journal of Supportive Oncology, 7(6), 225-228. PMID: 20380330.
Google Scholar | Medline Smith, M. A., Ungerleider, R. S., Horowitz, M. E., Simon, R. (1991). Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing’s sarcoma. Journal of the National Cancer Institute, 83, 1460-1470. https://doi.org/10.1093/jnci/83.20.1460
Google Scholar | Crossref | Medline Spunt, S. L., Irving, H., Frost, J., Sender, L., Guo, M., Yang, B. B., Dreiling, L., Santana, V. M. (2010). Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. Journal of Clinical Oncology, 28(8), 1329-1336. https://doi.org/10.1200/JCO.2009.24.8872
Google Scholar | Crossref | Medline Sung, L., Nathan, P. C., Lange, B., Beyene, J., Buchanan, G. R. (2004). Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: A meta-analysis of randomized controlled trials. Journal of Clinical Oncology, 22(16), 3350-3356. https://doi.org/10.1200/JCO.2004.09.106
Google Scholar | Crossref | Medline te Poele, E. M., Kamps, W. A., Tamminga, R. Y. J., Leeus, J. A., Postma, A., de Bont, E. S. J. M. (2005). Pegfilgrastim in pediatric cancer patients. Journal of Pediatric Hematology Oncology, 27(11), 627-629. https://doi.org/10.1097/01.mph.0000188631.41510.23
Google Scholar | Crossref | Medline Weycker, D., Li, X., Figueredo, J., Barron, R., Tzivelekis, S., Hagiwara, M. (2016). Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: Does timing of administration matter? Supportive Care in Cancer, 24(5), 2309-2316. https://doi.org/10.1007/s00520-015-3036-7
Google Scholar | Crossref | Medline Weycker, D., Li, X., Tzivelekis, S., Atwood, M., Garcia, J., Li, Y., Reiner, M., Lyman, G. H. (2017). Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Supportive Care Cancer, 25(2), 439-447. https://doi.org/10.1007/s00520-016-3421-x
Google Scholar | Crossref | Medline Whitworth, J., Matthews, K., Shipman, K., Numnum, T., Kendrick, J., Kilgore, L., Straughn, J. M. (2009). The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecologic Oncology, 112, 601-604. https://doi.org/10.1016/j.ygyno.2008.10.025
Google Scholar | Crossref | Medline Wicki, S., Keisker, A., Aebi, C., Leibundgut, K., Hirt, A., Ammann, R. (2008). Risk prediction of fever in neutropenia in children with cancer: A step towards individually tailored supportive therapy? Pediatric Blood and Cancer, 51, 778-783. https://doi.org/10.1002/pbc.21726
Google Scholar | Crossref | Medline Yang, B., Kido, A. (2011). Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clinical Pharmacokinetics, 50(5), 295-306. https://doi.org/10.2165/11586040-000000000-00000
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif